Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

Anjum Bashir Khan, MBChB, MRCP, Donal McLornan, MD, PhD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Kavita Raj, MD, PhD, MRCP, FRCPath, Victoria T Potter, MBBS, FRCPA, FRACP, Hugues de Lavallade, MD, Majid A Kazmi, BmedBiol MB ChB MRCP (UK) MRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Sangeeta Atwal, MBBS MRCP FRCPath, Victor Noriega, MD, Claire N Harrison, DM FRCP FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4532.

https://doi.org/10.1182/blood.V120.21.4532.4532

Published: 2012

Journal Articles

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Austin G Kulasekararaj, Alexander E Smith, PhD, Syed A Mian, Pramila Krishnamurthy, Azim M Mohamedali, PhD, Nicholas C Lea, PhD, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, Sabine Pomplun, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 792.

https://doi.org/10.1182/blood.V118.21.792.792

Published: 2011

Journal Articles

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

Jie Jiang, PhD, Austin G Kulasekararaj, Pramila Krishnamurthy, Alexander E Smith, PhD, Syed A Mian, Shreyans Gandhi, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 3826.

https://doi.org/10.1182/blood.V118.21.3826.3826

Published: 2011

Journal Articles

Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT

Victoria J Tindell, MBChB, Victoria T Potter, BSc, MBBS, Rachel Kesse-Adu, MBBS, Laura Reiff-Zall, Aloysius Y Ho, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Judith C. W. Marsh, MD, ZiYi Lim, MD

Blood (2010) 116 (21): 1331.

https://doi.org/10.1182/blood.V116.21.1331.1331

Published: 2010

Journal Articles

Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

Blood (2010) 116 (21): 125.

https://doi.org/10.1182/blood.V116.21.125.125

Published: 2010

Journal Articles

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Shreyans A Gandhi, MBBS, MD, DNB, MRCP, Victoria T Potter, BSc, MBBS, Victoria J. Tindell, MBChB, Rachel Kesse-Adu, MBBS, Laura Reiff-Zall, Michelle Kenyon, Judith C. W. Marsh, MD, Aloysius Y Ho, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, ZiYi Lim, MD

Blood (2010) 116 (21): 1304.

https://doi.org/10.1182/blood.V116.21.1304.1304

Published: 2010

Journal Articles

Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS

Victoria T Potter, BSc, MBBS, Victoria J Tindell, MBChB, Rachel Kesse-Adu, MBBS, Janet Hayden, Patience Pasipanodya, Laura Reiff-Zall, Judith C. W. Marsh, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Aloysius Y Ho, ZiYi Lim, MD, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2010) 116 (21): 2375.

https://doi.org/10.1182/blood.V116.21.2375.2375

Published: 2010

Journal Articles

A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab.

Aloysius YL Ho, MBBS, FRCP, FRCPath, Pramila Krishnamurthy, ZiYi Lim, MD, Michelle Kenyon, BSc, RN, Aleksander Mijovic, FRCPath, Stephen Devereux, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 2266.

https://doi.org/10.1182/blood.V114.22.2266.2266

Published: 2009

Journal Articles

Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion.

ZiYi Lim, MD, Sarah Bennett, Aloysius YL Ho, MBBS, FRCP, FRCPath, Austin G Kulasekararaj, Sunil Gupta, MBBS, MRCP, Michelle Kenyon, BSc, RN, Janet Hayden, Judith C W Marsh, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 3362.

https://doi.org/10.1182/blood.V114.22.3362.3362

Published: 2009

Journal Articles

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Judith C W Marsh, Vikas Gupta, ZiYi Lim, MD, David Marks, Edward C. Gordon-Smith, MD, BM, BCh, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 1084.

https://doi.org/10.1182/blood.V114.22.1084.1084

Published: 2009

Journal Articles

Increased Effector CD4 + T-Cells Early Post Hematopoietic Stem Cell Transplantation Using an Alemtuzumab-Based Reduced Intensity Conditioning Regimen Correlate with Subsequent Development of Graft Versus Host Disease.

Katie Matthews, PhD, ZiYi Lim, MD, Laurence Pearce, Msc, Khalid Tobal, PhD, Alejandro Madrigal, MD, PhD, Ghulam J. Mufti, MD, Linda D. Barber, PhD

Blood (2007) 110 (11): 4999.

https://doi.org/10.1182/blood.V110.11.4999.4999

Published: 2007

Journal Articles

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Karthik Ramasamy, MD, Shameem Mahmood, MD, Laurence Pearce, MD, ZiYi Lim, MD, Dariusz Ladon, PhD, Antonio Pagliuca, MD, Stephen Devereux, MD, PhD, Ghulam J. Mufti, MD, DM, Stephen Schey, MD

Blood (2007) 110 (11): 3034.

https://doi.org/10.1182/blood.V110.11.3034.3034

Published: 2007

NARROW

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT

Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS

A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab.

Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion.

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Increased Effector CD4 + T-Cells Early Post Hematopoietic Stem Cell Transplantation Using an Alemtuzumab-Based Reduced Intensity Conditioning Regimen Correlate with Subsequent Development of Graft Versus Host Disease.

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only